UNSPSC 51294517: Azaloxan fumarate

This classification denotes an antidepressant agent with the molecular formula C18H25N3O3.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8605L38D80, chemically known as (s)-1-(1-(2-(1,4-benzodioxan-2-yl)ethyl)-4-piperidyl)-2-imidazolidinon fumarat but more generally known as azaloxan fumarate, which bears US NIH Compound Identifier 6435451. Most nations, for tariff and trade purposes, schedule azaloxan fumarate under HS 29349990 and SITC 51579. As of Q4 2014, AZALOXAN FUMARATE remains US FDA's Preferred Term for this commodity.

Azaloxan fumarate bears US NLM identifiers UMLS ID C2346892 and NCI Concept Code C72710. SMILES: C1CCC2C(C1)OC[C@@H](O2)CCN3CCC(CC3)N4CCNC4=O.C(=C/C(=O)O)\C(=O)O.

UNSPSC 51294517 Azaloxan fumarate is a Commodity code nominally describing a single pharmaceutical product, but recent state and local opportunities tagged under this code show minimal direct alignment with the code's stated scope. The three recent opportunities address broader pharmaceutical and medication procurement — naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals with over-the-counter products — rather than azaloxan fumarate specifically. State and local issuing bodies using this code include county health departments (Seminole County, Florida), state health and human services commissions (Texas Health and Human Services Commission), and cooperative purchasing alliances serving multiple jurisdictions (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). The mismatch between the code's nominal scope and actual solicitation content suggests either broad tagging practices at the commodity level or misclassification in the opportunities system.

Recent activity spans Florida, Texas, and Minnesota. The most concrete recent opportunity is Seminole County's IFB 60459723LAS, posted June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida; the IFB response deadline was July 26, 2023 (note: the due date precedes the posting date, indicating a data anomaly in the source). Texas HHS issued RFI HHS0017013 in March 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescription program with an April 3, 2026 response deadline. MMCAP issued an RFP for generic multi-source pharmaceuticals and OTC products with a March 26, 2026 response deadline, effective July 1, 2026, requiring vendors to supply through three authorized wholesalers and meet FDA cGMP and Drug Supply Chain Security Act compliance. Given the scope mismatch, this code shows limited relevant activity for vendors targeting azaloxan fumarate procurement specifically.